March 9, 2014 | Israeli biomed company BiolineRX held a secondary public offering on Nasdaq. The offering is considered a success, as the company surpassed its goal of $21 million, raising $24 million. The company said that it will use the proceeds for clinical trials of its leukemia and celiac disease treatments.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israel Sending 20 Green Tech Firms To UN Climate Conference
October 06, 2024
Tel Aviv University Ranked 7th In World For Global Entrepreneurship
October 01, 2024
IIA Backs R&D By Startup Using Bacteria To Help Crops Grow
September 30, 2024
Facebook comments